Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94304, USA.
Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Sci Adv. 2022 Apr 22;8(16):eabj1360. doi: 10.1126/sciadv.abj1360. Epub 2022 Apr 20.
Treatment of acute lymphoblastic leukemia (ALL) necessitates continuous risk assessment of leukemic disease burden and infections that arise in the setting of immunosuppression. This study was performed to assess the feasibility of a hybrid capture next-generation sequencing panel to longitudinally measure molecular leukemic disease clearance and microbial species abundance in 20 pediatric patients with ALL throughout induction chemotherapy. This proof of concept helps establish a technical and conceptual framework that we anticipate will be expanded and applied to additional patients with leukemia, as well as extended to additional cancer types. Molecular monitoring can help accelerate the attainment of insights into the temporal biology of host-microbe-leukemia interactions, including how those changes correlate with and alter anticancer therapy efficacy. We also anticipate that fewer invasive bone marrow examinations will be required, as these methods improve with standardization and are validated for clinical use.
治疗急性淋巴细胞白血病 (ALL) 需要持续评估白血病疾病负担和免疫抑制背景下发生的感染风险。本研究旨在评估杂交捕获下一代测序 (NGS) panel 的可行性,该 panel 可在 20 例接受诱导化疗的 ALL 儿科患者中进行纵向测量分子白血病疾病清除率和微生物物种丰度。这一概念验证有助于建立一个技术和概念框架,我们预计该框架将扩展并应用于更多白血病患者,并扩展到其他癌症类型。分子监测有助于加速了解宿主-微生物-白血病相互作用的时间生物学,包括这些变化如何与抗癌治疗效果相关联并改变其效果。我们还预计,随着这些方法的标准化和临床验证,侵入性骨髓检查的需求将会减少。